ImmunityBio (IBRX) Shares Outstanding (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Shares Outstanding (Entity) of $1.0 billion for Q1 2026, up 22.7% year-over-year from $853.6 million in Q1 2025, and up 3.51% quarter-over-quarter from $1.0 billion in Q4 2025.
ImmunityBio (IBRX) Shares Outstanding (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Shares Outstanding (Entity) for 13 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 22.7% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 22.7% YoY), while the FY2025 annual figure was $1.0 billion, up 45.1% from the prior year.
- Shares Outstanding (Entity) rose to $1.0 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $1.0 billion in Q1 2026 and bottomed at $398.0 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $652.5 million across 5 years, with a median of $677.0 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 1.47% — and 2024, when it jumped 56.99%.
- ImmunityBio's Shares Outstanding (Entity) stood at $435.9 million in 2022, then advanced by 16.68% to $508.6 million in 2023, then surged by 37.09% to $697.3 million in 2024, then jumped by 45.1% to $1.0 billion in 2025, then increased by 3.51% to $1.0 billion in 2026.
- Business Quant data shows IBRX's Shares Outstanding (Entity) at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $985.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 919.86 Mn |
| Sep 30, 2025 | 946.60 Mn |
| Jun 30, 2025 | 888.22 Mn |
| Mar 31, 2025 | 853.16 Mn |
| Dec 31, 2024 | 697.31 Mn |
| Sep 30, 2024 | 695.90 Mn |
| Jun 30, 2024 | 686.94 Mn |
| Mar 31, 2024 | 672.83 Mn |
| Dec 31, 2023 | 508.64 Mn |
| Sep 30, 2023 | 498.38 Mn |
| Jun 30, 2023 | 437.46 Mn |
| Mar 31, 2023 | 428.38 Mn |
| Dec 31, 2022 | 399.90 Mn |
| Sep 30, 2022 | 400.06 Mn |
| Jun 30, 2022 | 397.99 Mn |
| Mar 31, 2022 | 397.88 Mn |
| Dec 31, 2021 | 389.23 Mn |
| Sep 30, 2021 | 391.85 Mn |